Posted by Michael Wonder on 03 May 2021
ImmunoMet Therapeutics granted fast track designation by U.S. FDA for IM156 in idiopathic pulmonary fibrosis
3 May 2021 - ImmunoMet Therapeutics today announced that the U.S. FDA has granted fast track designation for its lead compound IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis.
IM156 is a Protein Complex 1 inhibitor that targets the oxidative phosphorylation pathway, decreasing the supply of energy and anabolic precursors that are required to drive fibrotic disease and tumour growth.
